Attached files

file filename
EX-10.25 - EX-10.25 - vTv Therapeutics Inc.vtvt-ex1025_142.htm
10-K - 10-K - vTv Therapeutics Inc.vtvt-10k_20191231.htm
EX-32.2 - EX-32.2 - vTv Therapeutics Inc.vtvt-ex322_7.htm
EX-32.1 - EX-32.1 - vTv Therapeutics Inc.vtvt-ex321_6.htm
EX-31.2 - EX-31.2 - vTv Therapeutics Inc.vtvt-ex312_9.htm
EX-31.1 - EX-31.1 - vTv Therapeutics Inc.vtvt-ex311_13.htm
EX-21.1 - EX-21.1 - vTv Therapeutics Inc.vtvt-ex211_8.htm
EX-10.26 - EX-10.26 - vTv Therapeutics Inc.vtvt-ex1026_143.htm
EX-4.3 - EX-4.3 - vTv Therapeutics Inc.vtvt-ex43_144.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

 

(1)

Registration Statement (Form S-8 No. 333-206335) pertaining to the vTv Therapeutics Inc. 2015 Omnibus Equity Incentive Plan, and

 

(2)

Registration Statement (Form S-3 No. 333-223269) of vTv Therapeutics Inc., and

 

(3)

Registration Statement (Form S-3 No. 333-232571) of vTv Therapeutics Inc.;

of our report dated February 20, 2020 with respect to the consolidated financial statements of vTv Therapeutics Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2019.

/s/ Ernst & Young LLP

Raleigh, North Carolina

February 20, 2020